All.Can – changing cancer care together

Regions covered:


Completed date:
Policy theme:
efficiency, waste, patient outcomes, innovation
Disease area:
Key partners and stakeholders:

Association of European Cancer Leagues
Centre for Health Care, National Institute of Public Health, Slovenia
Clinique de Genolier
European Hospital and Healthcare Federation (HOPE)
European Cancer Patients Coalition
European Organisation for Research and Treatment of Cancer (EORTC)
GVG-Committee on Health Goals
International Brain Tumour Alliance
International Consortium for Health Outcomes Measurement (ICHOM)
Lieve Wierinck MEP
Marivek Health Consulting
Melanoma Patients Network Europe
Mélanome France
Oncopole-Sciences du Vivant et Santé Publique
Polish Cancer Patient Coalition
Save Your Skin Foundation Canada
University of Basel
Bristol-Myers Squibb

Signature output:
All.Can policy report

About this project

All.Can is a new policy initiative which aims to engage policymakers on the need to improve the efficiency of cancer care, focusing on better outcomes for patients.

The Health Policy Partnership provides secretariat for All.Can, a multidisciplinary, multi-sectoral European initiative which aims to identify ways we can optimise the use of our resources in cancer care. All.Can is backed by leading representatives from patient organisations, policymakers, healthcare professionals, research and industry.

Visit the All.Can website for more information about All.Can, including members, publications, news and event.


All.Can activities for 2017 will include:

  • Leading and commissioning research to gather evidence on where system inefficiencies exist, and help identify ways to improve efficiency in cancer care
  • Developing concrete tools and platforms for stakeholders to work together to ensure cancer care decisions are focused on what matters most to patients, and resources are used as effectively as possible
  • Helping to implement concrete policy actions based on these findings.

If you have questions about the All.Can initiative, please contact Suzanne Wait at

The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (lead sponsor), Amgen and MSD (co-sponsors). None of the content of All.Can discussions or activities is specific or biased to any specific treatment or therapy. All members contribute their time for free to the initiative, and all publications from the group reflect consensus of the members, who hold full editorial control.

Other projects